Safety and efficacy evaluation of combined pelvic organ resection for locally advanced pelvic malignancy: a prospective cohort study

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100043068

Enrollment

Unknown

Registered

2021-02-04

Start date

2021-03-01

Completion date

Unknown

Last updated

2021-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pelvic malignancy

Interventions

Patients with pelvic malignancies: combined pelvic organ resection

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Preoperative pathology was confirmed to be pelvic malignant tumor; (2) No distant metastasis was found in preoperative imaging examination; (3) Preoperative multidisciplinary discussion (MDT) confirmed surgical indications; (4) Intraoperative exploration Tumors involving the vagina, uterus, bladder, ureters, seminal vesicle glands, etc. require combined organ resection; (5) There is no contraindication to surgery such as serious heart and lung diseases.

Exclusion criteria

Exclusion criteria: (1) Those who cannot tolerate surgery due to severe heart and lung diseases; (2) The affected party refuses to undergo combined organ resection.

Design outcomes

Primary

Measure	Time frame
Quality of Life;complication;3-year survival rate;	—

Countries

China

Contacts

Public ContactHui Yang

Sichuan Cancer Hospital & Institute

910638755@qq.com+86 18908191080

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026